Mapi - Pharma (Mapi - Pharma) Total Inventories : $0.00 Mil (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Total Inventories?

Mapi - Pharma's total inventories for the quarter that ended in Jun. 2015 was $0.00 Mil. Mapi - Pharma's average total inventories from the quarter that ended in Dec. 2014 to the quarter that ended in Jun. 2015 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Mapi - Pharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2015 was $0.22.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mapi - Pharma Total Inventories Historical Data

The historical data trend for Mapi - Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Total Inventories Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Total Inventories

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Total Inventories	-	-	-	-	-

Mapi - Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Mapi - Pharma (NAS:MAPI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Mapi - Pharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2015 is

	Net-Net Working Capital Per Share (Q: Jun. 2015 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(12.304	+	0.75 * 0	+	0.5 * 0	-	10.3
-	0.431	-	0)	/	7.057
=	0.22

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Mapi - Pharma's Days Inventory for the six months ended in Jun. 2015 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2015 )	/	Cost of Goods Sold (Q: Jun. 2015 )	*	Days in Period
	=	0	/	0	*	365 / 2
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Mapi - Pharma's Inventory Turnover for the quarter that ended in Jun. 2015 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2015 )	/	Average Total Inventories (Q: Jun. 2015 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mapi - Pharma's Inventory to Revenue for the quarter that ended in Jun. 2015 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2015 )	/	Revenue (Q: Jun. 2015 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Mapi - Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.